VRM
FLGT icon

Vectors Research Management’s Fulgent Genetics FLGT Stock Holding History

Vectors Research Management’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-20
Closed -$1K – 264
2022
Q2 		$1K Hold
20
– – ﹤0.01% 485
2022
Q1 		$1K Hold
20
– – ﹤0.01% 446
2021
Q4 		$2K Hold
20
– – ﹤0.01% 555
2021
Q3 		$2K Hold
20
– – ﹤0.01% 455
2021
Q2 		$2K Hold
20
– – ﹤0.01% 475
2021
Q1 		$2K Buy
+20
New +$2.06K ﹤0.01% 423

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Vectors Research Management's FLGT Position: Q3 2022 in Review

Vectors Research Management sold out of Fulgent Genetics (FLGT) in Q3 2022, closing a stake of 20 shares — an estimated $1K sold.

Vectors Research Management first reported a position in FLGT in Q1 2021 and held it in 6 quarters. The position peaked at $2K in Q4 2021. 235 funds tracked by Wall St. Rank hold FLGT as of Q3 2022.

  • Vectors Research Management reported no remaining Fulgent Genetics position as of Q3 2022 after selling out during the quarter.
  • Vectors Research Management sold 20 Fulgent Genetics shares in Q3 2022, an estimated $1K.
  • Vectors Research Management first reported a position in Fulgent Genetics in Q1 2021 and held it in 6 quarters.
  • Vectors Research Management's Fulgent Genetics position peaked at $2K in Q4 2021.
  • 235 funds tracked by Wall St. Rank held Fulgent Genetics as of Q3 2022.

Based on Vectors Research Management's 13F filing for Q3 2022, filed 8 Nov 2022.